Oslo University Hospital Clinical Trials
Sponsors / Oslo University Hospital
622 ClinicalTrials.gov entries name Oslo University Hospital as the lead sponsor. The portfolio currently includes 79 recruiting studies, 56 active non-recruiting studies, and 335 completed studies. 24 trials in this portfolio were terminated or withdrawn before completion. The most common reasons cited for termination include slow or insufficient recruitment, business or strategic decisions. Cumulative planned enrollment across all listed trials is 278,435 participants. These counts reflect the current state of the public ClinicalTrials.gov registry.
622
Total Trials
79
Recruiting
56
Other Active
335
Completed
24
Terminated / Withdrawn
278,435
Total Enrollment
Termination reasons: Other58% · Recruitment38% · Business4%
Recent Terminations
- Cardiovascular Diseases"Slow recruitment"
- Anticoagulant-Induced Bleeding"Lack of resources"
- NCT06290856 Stopped Jul 2024Cholangiocarcinoma"The platform used for detecting ctDNA was not sensitive enough."
- NCT04557007 Stopped Oct 2022NSCLC"Difficulty recruiting"
- Amputation"Recruitment and technical difficulties"
- Chronic Subdural Hematoma"DMC concluded that the results of 382 included patients were clear."
- Non-small Cell Lung Cancer"slow recruiting"
- NCT02987309 Stopped Feb 2020Children"Equipment failure"
- Colorectal Cancer"Sponsor decision"
- Collar Treatment of Stable Subaxial Spine Fractures"Only 32 patients included in 21 months"
Active Trials (56 total)
- NCT03631173
- NCT05030922
- NCT05269225
- NCT05297266
- NCT05487820
- NCT02914912
- NCT07039773
- NCT06055205
- NCT07449897
- NCT07453420
- NCT06497101
- NCT07403331
- NCT07428694
- NCT05129787
- NCT05367310
- Chemotherapy Effect PHASE2NCT06313203
- NCT04529304
- NCT06297902
- NCT04803838
- Colorectal Adenocarcinoma PHASE2NCT05504252